Core Viewpoint - The Hong Kong stock market is expected to fully recover in 2025 after experiencing a significant downturn from 2021 to 2024, with the Hang Seng Index dropping over 50% during that period. The market is now witnessing a resurgence driven by technological breakthroughs and strong IPO activity, leading to record levels in various capital market dimensions [1]. IPO Performance - The IPO scale in Hong Kong is projected to exceed 300 billion HKD in 2026, with 2025 expected to see an IPO scale of 286.3 billion HKD, reclaiming the title of the world's largest IPO market [2][3]. - Eight companies in the top ten IPOs of 2025 raised over 10 billion HKD each, with many being A-share companies listed in Hong Kong [3]. - The IPO failure rate has decreased significantly, reaching a low of 28.83% in 2025, attributed to market conditions and new pricing mechanisms implemented by the Hong Kong Stock Exchange [4]. New Share Subscription Records - The Hong Kong market has set multiple records in new share subscriptions, including a historic oversubscription of 11,465 times for the IPO of Jinye International Group, marking the highest oversubscription in Hong Kong's history [5]. Refinancing Market - The refinancing scale in Hong Kong surpassed 300 billion HKD in 2025, with a total of 3,166 billion HKD raised, significantly exceeding the total from the previous three years [6][7]. - Leading companies like Xiaomi and BYD are at the forefront of major refinancing projects, raising substantial amounts for business expansion and development [8]. Stock Index Performance - The Hang Seng Index recorded a year-to-date increase of 28.49% as of December 23, 2025, positioning it among the top global stock indices [9]. - Sectors such as innovative pharmaceuticals and non-ferrous metals have shown remarkable performance, with stocks like Yaojie Ankang experiencing a staggering increase of 950.95% [10]. Capital Inflows and Buybacks - Southbound capital inflows into the Hong Kong market reached a record high of approximately 1.41 trillion HKD in 2025, significantly enhancing market liquidity [11][12]. - Stock buybacks by listed companies totaled 1,759.36 billion HKD in 2025, with Tencent leading the buyback amounts [13][14]. - Dividends distributed by Hong Kong companies reached nearly 1.46 trillion HKD, surpassing the total for the entire year of 2024 [15]. Delisting Trends - The pace of delistings in Hong Kong accelerated in 2025, with 61 companies exiting the market, primarily due to privatization and forced delisting mechanisms [16].

Core Viewpoint - The company, Xinji Pharmaceutical, is a clinical-stage innovative pharmaceutical technology enterprise that relies heavily on CRO (Contract Research Organization) services and MAH (Marketing Authorization Holder) business, with no self-developed commercialized products to date [1][2]. Business Model and Operations - Xinji Pharmaceutical's core business focuses on the development and commercialization of high-end formulation new drugs, utilizing two main technology platforms: soluble microneedle formulations and nasal inhalation formulations [1]. - The company has no self-developed commercialized products, with revenue primarily derived from CRO services and MAH business [1]. - The MAH business previously included sales of esomeprazole magnesium sustained-release capsules and propofol emulsion injection, but the propofol product was discontinued in January 2024, leaving only esomeprazole magnesium sustained-release capsules [1]. Revenue and Changes - The company's revenue has shown volatility over the past three years, with a 9.4% decline in 2024 due to a contraction in MAH business, while the first half of 2025 saw a recovery driven by increased CRO service orders [2]. - Revenue figures (in million RMB) are as follows: 2023: 541.20, 2024: 490.0 (down 9.4%), 2025 (H1): 281.0 (up 23.8% compared to 2024) [2]. Profit and Loss - The company has experienced continuous net losses over the past three years, with a significant increase in losses of 131% in 2024, totaling over 300 million RMB in cumulative losses [3]. - Net loss figures (in million RMB) are as follows: 2023: 0, 2024: +131.0%, 2025 (H1): -22.1% compared to 2024 [3]. Gross and Net Margins - The company's gross margin has declined by 7.4 percentage points over three years, with a gross margin of 27.7% in the first half of 2025, primarily due to the increasing proportion of lower-margin CRO services [4]. - Gross margin figures are as follows: 2023: 35.1%, 2024: 33.7% (down 1.4 percentage points), 2025 (H1): 27.7% (down 6.0 percentage points) [4]. Revenue Composition - In 2024, CRO service revenue accounted for 72.3% of total revenue, while MAH business revenue dropped to 27.7% [7]. - Following the discontinuation of propofol emulsion injection, the MAH business now relies solely on esomeprazole magnesium sustained-release capsules, which face pricing and competition risks [7]. Customer and Supplier Concentration - The company has seen a significant increase in customer concentration, with the top five customers contributing 58.1% of revenue in the first half of 2025, up from 48.6% in 2023 [8]. - Supplier concentration is also high, with the top five suppliers accounting for 55.7% of purchases, indicating a reliance on a limited number of suppliers for core production [9]. Shareholder Structure - The company is controlled by the Wu Chuanbin family, holding 51.01% of shares, leading to a concentrated ownership structure that may pose risks related to decision-making and potential conflicts of interest [10]. Management Team - The management team, led by Chairman Wu Chuanbin, has a strong research background but lacks extensive commercial experience, raising concerns about the company's ability to effectively commercialize its products [11]. Financial Risks - The company faces significant financial risks, including a high debt-to-asset ratio of 687% and insufficient cash reserves to sustain operations beyond three months [13].

12月23日，由成都市经信局市新经济委、成都高新区生物产业局、毕马威企业咨询（中国）有限公司联合主办，天府锦城实验室（前沿医学中心）承办 的"港股IPO战略全周期：从架构设计到财务合规的实战路径"主题沙龙在成都高新区顺利举行。作为Bio商学院系列主题沙龙2025年第Ⅳ期活动，本期聚 焦于港股IPO全周期筹备策略，为拟赴港上市的创新药械及生命科学企业提供实战指引，助力企业精准把握上市机遇，对接国际资本市场。 活动吸引了生物医药产业拟上市企业的创始人、董秘、财务及投融资负责人80余位代表参加，围绕港股2025年市场动态、18A章上市机制、财务合规、税 务架构、公司治理与内控等核心议题展开深度交流与专业探讨。 2025年以来，港股市场表现活跃，融资规模重回全球前列，生物医药、前沿科技成为IPO主力赛道之一。在"一带一路"合作深化、生命科技全球化加速、 港股政策持续优化等背景下，香港资本市场已成为中国创新药械企业走向国际的重要枢纽。特别是港股18A章为尚未盈利的生物科技企业提供了上市通 道，助力企业提前登陆资本市场，获取关键发展资金。 沙龙在毕马威中国及合作机构的专业支持下，系统解析了港股IPO从Pre-IPO筹备到 ...

编者按： 随着中国资本市场双向开放向纵深推进，中资券商化身"金融航海家"，驶向更广阔的全球市场。它们以跨 境投行连接东西，用财富管理服务民生，足迹遍布香港中环、伦敦金融城和纽约华尔街等金融枢纽，在国 际资本市场发出"中国声音"。证券时报携手中国证券业协会推出"券商'出海'进行时"栏目，全景展现中资 券商从合规经营到本土化融合、从跟跑到领跑的心路历程——诠释中国资本市场如何从"参与者"蜕变 为"规则制定者"，在开放浪潮中书写高质量发展新篇章。本文为专栏第十三篇，敬请垂注！ 随着全球经济复苏和新兴产业崛起，立足于香港这个国际金融中心之一的港股市场，正吸引着越来越多企 业前来上市融资以实现跨越式发展。 近日，平安证券投资银行事业部副总经理彭朝晖在接受证券时报记者采访时表示："港股市场作为企业出海融 资的重要平台，具有诸多优势。平安证券凭借在境内外投行联动、行业聚焦、战略规划和战术执行等方面的优 势，为企业提供了全方位、专业化的港股IPO服务。" 在他看来，这主要有两方面的原因：一方面，随着全球经济复苏和新兴产业崛起，企业对资金的需求日益增 长，港股市场丰富的资金来源和多元化的投资者结构为企业提供了广阔的融资空间；另 ...

近日，平安证券投资银行事业部副总经理彭朝晖在接受证券时报记者采访时表示："港股市场作为企业出海融资的 重要平台，具有诸多优势。平安证券凭借在境内外投行联动、行业聚焦、战略规划和战术执行等方面的优势，为 企业提供了全方位、专业化的港股IPO服务。" 深谙港股市场优势 证券时报记者 谭楚丹 随着全球经济复苏和新兴产业崛起，立足于香港这个国际金融中心之一的港股市场，正吸引着越来越多企业前来 上市融资以实现跨越式发展。 彭朝晖称，过去一年来，港股市场吸引了全球众多企业纷纷登陆，金融、科技、消费、医疗等多个领域的企业均 将港股市场视为重要的融资渠道。 在他看来，这主要有两方面的原因：一方面，随着全球经济复苏和新兴产业崛起，企业对资金的需求日益增长， 港股市场丰富的资金来源和多元化的投资者结构为企业提供了广阔的融资空间；另一方面，港股市场在国际金融 市场的地位、国际接轨方面的上市规则和监管机制，可以帮助企业更好地融入全球资本市场。 在机制层面，港股市场具有显著优势。彭朝晖解释，在投资者结构上，港股市场以机构投资者为主，有效减少了 股价的短期波动，更能反映企业的长期价值；从募资效率来看，港股上市周期通常在6~9个月；在再融 ...

Group 1 - The core viewpoint of the article discusses the recent decline in Hong Kong stocks, particularly in contrast to the recovery of US and A-shares, with a notable decrease in average daily trading volume since September [1] - The report from China Merchants Securities International attributes the decline to changes in the funding situation, including the "crowding out effect" of southbound funds, which has led to a withdrawal of capital from Hong Kong back to A-shares [1] - As of the third quarter of 2025, the scale of actively managed equity public funds was 3.59 trillion yuan, with a benchmark for Hong Kong stock holdings at 356 billion yuan, while actual holdings were 594 billion yuan, indicating a significant discrepancy [1] Group 2 - Recent reports indicate a slowdown in southbound fund inflows, with the 10-day moving average dropping from an average of 7 billion HKD to less than 1 billion HKD since late November 2025, with some periods even showing net outflows [3] - The number of IPOs in Hong Kong is expected to rise significantly in 2026, with 99 companies having raised over 250 billion HKD as of December 12, 2025, compared to 50 companies raising nearly 90 billion HKD in 2024 [3] - The anticipated IPO financing scale for 2026 is projected to be around 330 billion HKD, with 314 listing applications already in process as of December 12, 2025 [3] Group 3 - External liquidity disturbances are considered a major factor affecting the performance of Hong Kong stocks, with the report from GF Securities highlighting that Hong Kong stocks are influenced by both domestic fundamentals and overseas liquidity [5] - The consensus earnings growth forecast for the Hang Seng Index for 2025 has been revised down to -8.49%, indicating a negative outlook for profitability [5] - The recent market fluctuations may reflect that these conditions have already been priced in, suggesting that the current situation may not be as concerning as it appears [5]

文｜氨基观察 2025年风光无限的港股18A新股暴涨神话，今日正式破灭。 12月22日，18A生物科技公司华芢生物登陆港交所，与此前18A新股上市后动辄大涨的火热行情形成鲜 明反差，公司股价首日便遇冷走弱。截至收盘，华芢生物收跌29.32%，给市场泼了一盆冷水。 值得注意的是，首日破发的并非只有华芢生物。同日，明基医院、印象大红袍、南华期货3只港股新股 同步挂牌，最终全部加入破发行列，形成"集体遇冷"的局面。 截至当日收盘，明基医院暴跌49.46%，据Wind数据显示，该跌幅已创下年内港股新股首日最差纪录； 印象大红袍、南华期货分别下跌35.28%、24.17%。 此次多股集体破发，背后是港股IPO市场的双重压力：一方面，监管层近期已明确释放收紧信号，对上 市申请材料质量、保荐机构合规行为等提出更高要求；另一方面，2025年港股IPO数量大幅扩容，尤其 是近期新股发行密度激增，市场流动性被持续分流。 在这一背景下，港股新股的破发概率已明显攀升。对于后续拟赴港上市的企业而言，尤其是依赖市场情 绪支撑的18A类公司，上市难度或将进一步加大，市场对新股的筛选也将更趋严苛。 / 01 /赚钱效应下的狂欢 在华芢生物上 ...

Core Viewpoint - Liuliu Fruit Garden's parent company, Liuliu Mei, has received approval from the China Securities Regulatory Commission for its overseas listing and the full circulation of its unlisted shares in the domestic market, indicating a significant step towards its IPO on the Hong Kong Stock Exchange [3] Group 1: Company Overview - Liuliu Fruit Garden plans to issue up to 19.37 million overseas listed ordinary shares and convert approximately 67.35 million domestic unlisted shares into overseas listed shares, achieving full circulation of shares [3] - The company has been a leader in the fruit snack industry since launching its classic brand in 2001, focusing on the plum product sector and developing a diverse product matrix including dried plums, plum jelly, and plum soft candies [3][4] Group 2: Market Position - According to Frost & Sullivan data, Liuliu Fruit Garden ranks first in China's fruit snack industry with a retail market share of 4.9% and leads the natural ingredient jelly sector with a market share of 45.7% [4] - The company has also entered the top tier of the jelly industry with a 2.9% market share, establishing itself as a core leader in the natural ingredient jelly field [4] Group 3: IPO Fund Utilization - The funds raised from the IPO will be allocated to four main areas: expanding production capacity for dried plums and jellies, enhancing brand awareness and sales networks, recruiting R&D personnel to strengthen technological capabilities, and providing operational funds for sustainable development [4]

Core Viewpoint - The recent collective decline of four new stocks on their debut in the Hong Kong market is attributed to multiple factors, including tightening liquidity and a mismatch between high valuations and fundamental performance [2][4]. Group 1: New Stock Performance - Four new stocks listed on December 22, 2025, experienced significant declines on their first trading day: Mingji Hospital down 49.46%, Impression Dahongpao down 35.28%, Huazai Bio down 29.32%, and Nanhua Futures down 24.17% [2][6]. - This trend of new stocks underperforming is not isolated; over half of the 17 new stocks listed in December 2025 have also seen their prices drop on the first day [4]. - In contrast, the overall performance of new stocks throughout 2025 was strong, with 76 out of 102 new listings seeing price increases, and 16 stocks achieving over 100% cumulative gains [5]. Group 2: Market Environment - The Hong Kong stock market is facing a weakening liquidity environment, with average daily trading volume dropping below 200 billion HKD and southbound capital inflows significantly decreasing [2][7]. - Southbound capital net inflow for December 2025 was only 21.91 billion RMB, a stark contrast to previous months where inflows often exceeded 100 billion RMB [8]. Group 3: Factors Behind Weakness - Internal factors contributing to the weak liquidity include new regulations for public funds that may lead to net selling of Hong Kong stocks, as many funds are overexposed compared to their benchmarks [9]. - The high demand for funds in the Hong Kong market is also influenced by a backlog of over 300 companies waiting to go public, which adds pressure to the existing liquidity [9]. Group 4: Individual Stock Fundamentals - Mingji Hospital's high valuation is under scrutiny, with a price-to-earnings (PE) ratio of approximately 29.8, compared to the average PE of 17 for private hospitals in Hong Kong. Its revenue and profit have also declined year-on-year [11][12]. - Impression Dahongpao has similarly reported a decrease in profit, with figures of 42.86 million RMB and 10.23 million RMB for 2024 and the first half of 2025, respectively [12]. Group 5: IPO Mechanism Changes - The introduction of "Mechanism B" for IPOs allows issuers to set a lower limit on the public offering portion, which can lead to smaller trading volumes and potentially reduce mispricing risks. However, it may also hinder companies with high valuations from recovering through retail investor participation [13].

每经AI快讯，12月22日，中国证监会国际合作司发布关于北京智谱华章科技股份有限公司境外发行上 市及境内未上市股份"全流通"备案通知书，公司拟发行不超过43,032,400股境外上市普通股并在香港联 合交易所上市。 ...